Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients

Summary

Sufficient subjects with a confirmed diagnosis of MS (EDSS score of 6.5 or below), will be recruited to ensure that 30 subjects (approx. equal numbers of each gender) complete the study. Subjects will undergo a screening visit, then four study days, each separated by a washout period of at least 7 days, when the different firategrast batches of drug substance will be administered, and a follow-up visit.

Timeline

Start

2007-04-21

Primary completion

2007-11-26

Completion

2007-11-26

Drugs

Indications